首页> 美国卫生研究院文献>Springer Open Choice >Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

【2h】

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

机译：曲妥珠单抗氨丹宁在仅使用过曲妥珠单抗和帕妥珠单抗联合曲妥珠单抗治疗且仅在日本人群中治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundTrastuzumab emtansine (T-DM1) has been approved since 2013 for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who had received trastuzumab (Tmab) and taxane. However, no clinical trial has evaluated the efficacy of T-DM1 in those who have previously received pertuzumab (Pmab). This study aimed to compare the efficacy of T-DM1 between patients who had received Tmab and Pmab and those who had received Tmab only in Japanese population.

机译：背景自2013年以来，曲妥珠单抗（T-DM1）已被批准用于已接受曲妥珠单抗（Tmab）和紫杉烷的人类表皮生长因子受体2（HER2）阳性转移性乳腺癌（MBC）的患者。但是，尚无临床试验评估过T-DM1在先前接受过帕妥珠单抗（Pmab）治疗的患者中的疗效。这项研究旨在比较仅在日本人群中接受Tmab和Pmab的患者与接受Tmab的患者之间T-DM1的疗效。

著录项

期刊名称 Springer Open Choice
作者
Shoko Noda-Narita; Akihiko Shimomura; Asuka Kawachi; Hitomi Sumiyoshi-Okuma; Kazuki Sudo; Tatsunori Shimoi; Emi Noguchi; Kan Yonemori; Chikako Shimizu; Yasuhiro Fujiwara; Kenji Tamura;
展开▼
作者单位

展开▼
年(卷),期 -1(26),4
年度 -1
页码 492–498
总页数 7
原文格式 PDF
正文语种
中图分类外科学;
关键词
Trastuzumab emtansine Metastatic breast cancer Human epidermal growth factor 2 Trastuzumab Pertuzumab;

机译：曲妥珠单抗坦坦碱;转移性乳腺癌;人类表皮生长因子2;曲妥珠单抗;帕妥珠单抗;

相似文献

外文文献
中文文献
专利

1. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [J] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, Breast cancer . 2019,第4期

机译：曲妥珠单抗氨丹宁在先前使用曲妥珠单抗和帕妥珠单抗联合治疗以及仅在日本人群中联合曲妥珠单抗治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
2. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1) [J] . Baez-Vallecillo Luis, Raghavendra Akshara S., Hess Kenneth R., Breast cancer research and treatment. . 2019,第1期

机译：Lapatinib在转移性人体表皮生长因子受体2阳性乳腺癌中的活性，接受曲妥珠单抗，Pertuzumab和/或Ado-Trastuzumab Omtansine（T-DM1）的治疗
3. Effects of trastuzumab emtansine (T-DM1) on Qt interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer [J] . GuptaM., WangB., CarrothersT.J., Clinical pharmacology in drug development . 2013,第1期

机译：曲妥珠单抗Emtansine（T-DM1）对先前治疗过的人表皮生长因子受体2阳性转移性乳腺癌患者Qt间隔和帕妥珠单抗加T-DM1安全性的影响
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes [O] . Sasha Lupichuk, Winson Y Cheung, Douglas Stewart 2019

机译：帕妥珠单抗和曲妥珠单抗Emtansine用于人类表皮生长因子受体2阳性转移性乳腺癌：当代基于人群的结果。
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

摘要

著录项

相似文献

相关主题

期刊订阅